AstraZeneca reports positive results from Imfinzi trials
AstraZeneca
10,460.00p
17:00 27/12/24
0.23%
24.00p
AstraZeneca on Wednesday said its Imfinzi drug combined with chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC) after results from a phase III clinical trial.
FTSE 100
8,149.78
16:54 27/12/24
n/a
n/a
FTSE 350
4,495.62
16:29 27/12/24
n/a
n/a
FTSE All-Share
4,453.14
17:05 27/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,065.81
16:29 27/12/24
0.00%
20,065.81
Worldwide, 210,000 people are diagnosed with BTC each year with between 5%-15% surviving more than five years.
In a separate statement, the company said a combination of Imfinzi with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.
Results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive after three years.